SV Health Investors (SVHI), a healthcare and life sciences focused private investment firm, announced the acquisition of EpiVax, Inc. on April 2, 2026.123
EpiVax is a leading bioanalytical CRO specializing in immunogenicity risk assessments for pharmaceutical and biotech companies, founded in 1998, and headquartered in Providence, RI.123
The financial terms of the deal were not disclosed.12
The acquisition is a new platform investment for SVHI, providing EpiVax with strategic guidance, capital, and access to its life sciences ecosystem to accelerate growth and innovation.23
EpiVax plans to expand capabilities with advanced computational tools, cell-based assay applications, and broader analytical consulting services.23
Quotes from EpiVax Founder Annie De Groot and CEO Rich-Henry Schabowsky highlight confidence in the partnership for future growth.23
Sources:
1. https://nationaltoday.com/us/ma/boston/news/2026/04/02/sv-health-investors-acquires-epivax-1/
2. https://svhealthinvestors.com/news/sv-health-investors-acquires-epivax
3. https://nationaltoday.com/us/ri/providence/news/2026/04/02/sv-health-investors-acquires-epivax/